Tempus AI Stock Surges 14% on FDA Approval for Cardiac Imaging Platform

Tempus AI (TEM) shares jumped 14% Thursday after the FDA cleared an upgraded version of its AI-powered Tempus Pixel cardiac imaging platform. The stock has now gained 46% over the past month and 163% year-to-date as investors bet on the healthcare AI company's growth potential.

The 510(k) clearance enables advanced viewing and automated reporting of cardiac MR images, with new capabilities for generating T1 and T2 inline maps. This regulatory milestone follows Tempus AI's stronger-than-expected Q2 results and raised full-year guidance, with revenue surging 90% year-over-year.

While primarily a healthcare AI story, Tempus AI's success underscores the broader adoption of artificial intelligence across sectors—a trend that continues to drive interest in AI-adjacent crypto assets like FET, AGIX, and OCEAN.